Oncology and Carcinogenesis articles for South Korea

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 217

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
12 7.12
Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity 0.95
Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy 0.50
Nanomechanical Single-Cell Profiling Reveals Mechanical Dormancy Underlying Radiation Resistance in Polyploid Giant Cancer Cells 1.00
Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells 0.94
Collagenase-Functionalized Liposomes Overcome Stromal Barriers in Pancreatic Cancer 1.00
Engineering Multi-Functional Enzyme-Mimetic Polyphenol-Catalase Complex for Reversing Hypoxia and Redox Homeostasis in Vascular and Muscular Regeneration 1.00
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant 1.00
Pyroptosis-Inducing Nanoplatform with Plasmonic-Enhanced Phototherapy for Metastasis-Suppressive Cancer Immunotherapy 0.09
A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy 0.35
Harnessing Dye-Induced Local Heating in Lipid Membranes: A Path to Near-Infrared Light-Modulated Artificial Synaptic Vesicles 0.07
Advanced Cancer Liquid Biopsy Platform for miRNA Detection in Extracellular Vesicles Using CRISPR/Cas13a and Gold Nanoarrays 0.08
Thermosensitive Hydrogel Sustaining the Release of Lymph-Draining Oligonucleotide Adjuvant Polyplex Micelles Improves Systemic Cancer Immunotherapy 0.14
3 0.25
A biodegradable theranostic sonosensitizer for afterglow-guided sonodynamic therapy 0.08
Enhancing inter-system crossing efficiency of NIR-II emitting type-I photosensitizers for tumor ferroptosis induction 0.07
Self-propelled smart nanomotors for enhanced mild photothermal therapy of tumors through autophagy modulation 0.11
4 1.69
Coordination of Mechanodynamic Structure and Biochemical Signaling Restores ECM Soft‐Stiff Homeostasis for Anti‐Metastasis Tumor Therapy 0.02
Bimetallic Nanoreactor Activates cGAS-STING Pathway via mtDNA Release for Cancer Metalloimmunotherapy 1.00
Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME 0.45
Precise Quantification of Angiogenesis in 3D Biomaterials Using in Vitro CAM Models: Enhancing 3Rs in Research and Minimizing in Vivo Dependency 0.22
4 2.11
Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis 1.00
Molecularly Engineered Nanoagents with Efficient Free Radicals Generation and Photothermal Conversion Performance for Enhanced Tumor Photoimmunotherapy via Targeting Lactate Metabolism-Immune Circuit Rewiring 0.10
Photoinduced Plasmon Electron Transfer‐based Bioorthogonal Cleavage Reaction for Precision Tumor Therapy 0.84
Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma 0.17
1 0.03
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.03
2 1.25
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer 0.38
Deep Learning-Based Classification of NSCLC-Derived Extracellular Vesicles Using AFM Nanomechanical Signatures 0.88
6 1.38
Long-Acting Dynamic Therapy Using X-Ray Activated Organic Nanoparticles for Afterglow Imaging Guided Deep Tumor Treatment 0.08
Naphthalimide-Based Type-I Nano-Photosensitizers for Enhanced Antitumor Photodynamic Therapy: H2S Synergistically Regulates PeT and Self-Assembly 0.15
MitoSiege‐Driven Catalase Collapse: A GSH‐Responsive, Mitochondria‐Targeted COF Prodrug for Amplified Chemodynamic Therapy 0.45
A Photon‐Driven Unimolecular Immunostimulant for Self‐Amplified Pyroptosis and cGAS‐STING Pathway by Destroying the Pyroptosis Checkpoint 0.13
Engineering a Multifunctional Nanozyme Platform for Synergistic Melanoma Therapy: Integrating Enzyme Activity, Immune Activation, and Low‐Temperature Photothermal Effects 0.21
A Hypoxia‐Triggered Bioreduction of Hydrophilic Type I Photosensitizer for Switchable In Vivo Photoacoustic Imaging and High‐Specificity Cancer Phototherapy 0.36
4 2.46
Management of Responsive Lateral Pelvic Nodes After Neoadjuvant Therapy in Rectal Cancer (RESPONDER). 1.00
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.08
Two-Week Course versus Conventionally Fractionated Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision in Locally Advanced Rectal Cancer (Twoarc Trial): A Phase III Randomized Clinical Trial. 1.00
Effect of Double Layer Polyglycolic Acid Felt for Reducing Pancreatic Fistula After Pancreatoduodenectomy: Results of a Multicenter Randomized Control Trial (PLANET-PJ trial). 0.38
1 0.02
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.02
1 0.09
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.09
1 0.03
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression 0.03
6 2.18
Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma 1.00
Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors 0.86
C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 0.07
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. 0.16
Large-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness 0.06
The C-terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2 0.02
1 0.01
Rational discovery of therapeutic PAK1 allosteric activators 0.01
1 0.08
Zero-trigger ultrafast charge-transfer J-aggregates via Se/π-directed assembly enable synchronous ROS/heat amplification for NIR-II photoimmunotherapy 0.08
1 1.00
Impact of chronic lung disease, socioeconomic status, and family history on lung cancer risk in never-smokers: a matched case–control study 1.00
1 0.50
Unraveling the Inactivation Mechanisms of Human Adenovirus 2 in Sunlight Disinfection: Synergism between Direct and Indirect Pathways 0.50
1 0.05
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.05
1 0.84
APOBEC3A drives deaminase mutagenesis in human gastric epithelium 0.84
2 0.85
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 0.03
Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach 0.82
2 2.00
Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study. 1.00
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab. 1.00
1 0.14
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.14
1 1.00
Cumulative abdominal obesity exposure and progressive risk of endometrial cancer in young women: a nationwide cohort study 1.00
3 2.23
Preoperative Circulating Tumor DNA Detection and Risk Stratification in Esophageal Squamous Cell Carcinoma 1.00
Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer 0.23
Artificial Intelligence–Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer 1.00
2 1.14
The proton-sensing OGR1 receptor and hypoxia-inducible factors promote metal ion-induced inflammatory responses in coronary artery smooth muscle cells 0.14
Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2 1.00
3 3.00
Impact of Subtype Variability on Clinical Features in Papillary Thyroid Cancer 1.00
Long-term Nonskeletal Complications in Patients With Thyroid Cancer and Hypoparathyroidism Post Total Thyroidectomy 1.00
Diabetes Progression and Its Impact on Kidney Cancer Risk: Insights From a Longitudinal Korean Cohort Study 1.00
4 1.06
Iron overload in steatotic hepatocytes drives systemic metabolic dysfunction via alterations in hepatokine production 0.91
CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer 0.02
A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice 0.03
Inhibiting inflammation in adipocytes accelerates mammary tumor development in mice 0.10
20 1.57
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.05
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.13
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.08
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.08
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.04
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.05
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.09
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.13
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. 0.07
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.15
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.08
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.06
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. 0.11
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.02
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.07
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.12
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.12
4 2.24
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.08
Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer 1.00
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab 1.00
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 0.17
1 1.00
Differential prevalence and prognostic significance of spread through air spaces according to oncogenic driver mutations in lung adenocarcinoma 1.00
1 1.00
Effect of Anatomical Site on Prognosis and Progression Pattern in Early-Stage Acral Melanoma: A Retrospective Cohort Study of 281 Cases 1.00
5 0.94
Immune-Evasive NIR-II Nanoplatforms for Repeatable Photodynamic Therapy 0.29
NIR-II Nanomedicine Engineered CAR-NK Cells for Precision Navigation and Potentiating Lung Cancer Immunotherapy by Remodeling Tumor Microenvironment 0.08
Caged Ligand-Decorated Near-Infrared Photosensitizer with In Vivo Albumin-Hijacking Capacity for Tumor-Targeted Hypoxia-Tolerant Photoimmunotherapy of Cancer 0.20
Regioisomeric Engineering of Sterically Hindered Bright Near-Infrared Paraptosis Agents for Chemo-Photodynamic Therapy 0.20
Long-Lived Immunogenic Cell Death Induced by a Water-Soluble Redox Active Au(I) Bis-N-Heterocyclic Carbene 0.17
4 1.19
Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways 1.00
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.09
Breastfeeding after breast cancer in young iBRCA/i carriers 0.02
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.08
2 1.03
Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors 0.03
Mitochondrial fumarate inhibits Parkin-mediated mitophagy 1.00
2 0.58
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering 0.22
Bismuthene-Based Nanoplatform for Synergistic Thermogenetic CRISPR and Photothermal Cancer Therapy 0.36
4 1.21
Early fibrotic niches establish tumour-permissive microenvironments 0.38
The integrated stress response promotes immune evasion through lipocalin 2 0.17
Whole-genome landscapes of 1,364 breast cancers 0.52
Targeting FSP1 triggers ferroptosis in lung cancer 0.15
22 12.52
Periodontitis induces skeletal muscle atrophy by increasing circulating levels of activin A. 0.89
Activating p53Y220C with a mutant-specific small molecule 0.03
Discovery of a novel envelope protein derived from simian retrovirus 2 for pseudotyping retroviral vectors used for production of CAR immune cells 1.00
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.01
Recombinant haemostatic protein for therapeutic substitution of platelet function via tripartite haemostatic mechanisms in thrombocytopenic male mice 1.00
Subgroup performance of a commercial digital breast tomosynthesis model for breast cancer detection 0.23
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.04
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer 0.07
A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches 0.83
Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI 0.96
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer 0.02
Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection 0.03
The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells 0.96
Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 0.93
Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var 1.00
Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling 0.18
CD99-mediated immunological synapse formation potentiates CAR-T cell function 1.00
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 0.03
Opposing regulation of the K63-linked polyubiquitination of RIPK3 by SMURF1 and USP5 in necroptosis 1.00
DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species 1.00
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 0.33
Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity 0.98
10 0.86
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial 0.09
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.05
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 0.10
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.01
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.11
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.08
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.06
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial 0.18
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.08
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.10
1 0.01
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.01
2 1.25
Total Synthesis of WS9326B via a Bioinspired Macrolactonization Strategy 1.00
Asymmetric Total Synthesis of Daucane-Type Sesquiterpenoids (+)-Ferutinin and (+)-Kuhistanicaol G 0.25
1 1.00
Integrative transcriptomic analysis of Korean high-grade serous ovarian cancer 1.00
1 1.00
Evaluating the clinical utility of large language models for hepatocellular carcinoma treatment recommendations: A nationwide retrospective registry study 1.00
5 3.41
Integrated mutational landscape analysis of endometrial stromal sarcoma 0.15
Replication stress–induced nuclear hypertrophy alters chromatin topology and impacts cancer cell fitness 1.00
Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets 1.00
Tumor-promoting UBR4 coordinates impaired mitophagy–associated senescence and lung adenocarcinoma pathogenesis 0.85
Dual-laser “808 and 1,064 nm” strategy that circumvents the Achilles’ heel of photothermal therapy 0.40
12 11.40
Prevalence, Co-occurrence, and Prognostic Implications of S Modifiers in the Korean National Lung Cancer Screening Program. 0.82
Interreader Agreement and Diagnostic Confidence in Discriminating Masses and Nonmass Lesions at Breast US. 1.00
Preoperative Breast MRI and Survival Outcomes in Women 50 Years or Younger with Breast Cancer. 1.00
Recurrence Risk Following Percutaneous Transthoracic Needle Biopsy in Patients Undergoing Sublobar Resection for Stage I Lung Cancer. 1.00
Imaging Features and Diagnostic Performance of US in Nonmass Lesions with Varying Clinical Indications. 1.00
Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer. 1.00
Node Reporting and Data System Evaluation of Axillary Nodes in Invasive Ductal and Lobular Carcinoma. 1.00
External Testing of a Deep Learning Model for Lung Cancer Risk from Low-Dose Chest CT. 0.75
Prognostic Variability in Non-Small Cell Lung Cancer with Pathologic Separate Nodules in the Same Lobe at CT. 1.00
Invasive Breast Cancers Missed by AI Screening of Mammograms. 1.00
Pediatric Thyroid Nodules: K-TIRADS/ACR TI-RADS Pediatric-Specific Biopsy Cutoff Incorporating Clinical Risk Factors. 1.00
Preoperative Diagnosis of Ipsilateral and Contralateral Breast Cancer: Role of Diffusion-weighted MRI. 0.83
2 1.12
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation 0.90
Architecture of the UBR4 complex, a giant E4 ligase central to eukaryotic protein quality control 0.22
6 2.91
Circular RNA circHomer1 mediates hippocampal functions via ribonucleoprotein granule transport and dendritic targeting of synaptic RNAs 0.06
On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells 0.14
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer 0.70
EGFR activation requires cholesterol interaction at the inner leaflet of the plasma membrane 0.50
Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer 0.50
Radiotranscriptomics in papillary thyroid carcinoma complement current noninvasive risk stratification system 1.00
1 1.00
SDCBP/Syntenin-1 stabilizes BACH1 by disassembling the SCFFBXO22–BACH1 complex in triple-negative breast cancer 1.00
5 0.37
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.16
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.05
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial 0.07
15 1.52
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials 0.07
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.04
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial 0.27
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial 0.17
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.07
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.06
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.06
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.04
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.11
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study 0.09
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.04
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study 0.35
22 1.54
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.01
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.10
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.04
A Phase 3 Trial of Brepocitinib in Dermatomyositis 0.02
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.06
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.10
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.10
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.06
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.03
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.10
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.11
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.05
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.07
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.09
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.12
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.08
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.07
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.07
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.08

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.